Metagenomi Therapeutics (MGX) Cash from Financing Activities (2023 - 2026)
Metagenomi Therapeutics (MGX) posted quarterly Cash from Financing Activities of -$27000.0 for Q1 2026, up 64.94% year-over-year from -$16370.1 in Q1 2025, and down 136.49% quarter-over-quarter from $74000.0 in Q4 2025.
Metagenomi Therapeutics (MGX) Cash from Financing Activities (2023 - 2026) Analysis & Trends
Metagenomi Therapeutics (MGX) has reported Cash from Financing Activities for 4 consecutive years, with -$27000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Financing Activities rose 64.94% year-over-year to -$27000.0; the TTM figure through Mar 2026 stood at -$306000.0 (up 88.24% YoY), while the FY2025 annual figure was -$356000.0, down 100.42% from the prior year.
- Cash from Financing Activities eased to -$27000.0 in Q1 2026 per MGX's latest filing, from $74000.0 in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $86.5 million in Q1 2024 and bottomed at -$2.0 million in Q2 2024.
- Historically, Cash from Financing Activities has averaged $7.1 million across 4 years, with a median of -$121500.0 in 2025.
- On a YoY basis, Cash from Financing Activities climbed as much as 1914.83% in 2024 and fell as far as 5110.26% in 2024.
- Metagenomi Therapeutics' Cash from Financing Activities stood at -$1.3 million in 2023, then surged by 63.12% to -$492000.0 in 2024, then jumped by 115.04% to $74000.0 in 2025, then plunged by 136.49% to -$27000.0 in 2026.
- Business Quant data shows MGX's Cash from Financing Activities at -$27000.0 in Q1 2026, $74000.0 in Q4 2025, and -$187000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 14.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -6.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 36.24 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -16.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 27.18 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -273.15 Mn |
| 10 | Metagenomi Therapeutics | 46.51 Mn | 46.51 Mn | - | 67,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 67,000.00 |
| Jun 30, 2026 | 67,000.00 |
| Mar 31, 2026 | -27,000.00 |
| Mar 31, 2026 | -27,000.00 |
| Dec 31, 2025 | 74,000.00 |
| Dec 31, 2025 | 74,000.00 |
| Sep 30, 2025 | -187,000.00 |
| Sep 30, 2025 | -187,000.00 |
| Jun 30, 2025 | -166,000.00 |
| Jun 30, 2025 | -166,000.00 |
| Mar 31, 2025 | -77,000.00 |
| Mar 31, 2025 | -77,000.00 |
| Sep 30, 2024 | -492,000.00 |
| Sep 30, 2024 | -492,000.00 |
| Jun 30, 2024 | -2.03 Mn |
| Jun 30, 2024 | -2.03 Mn |
| Mar 31, 2024 | 86.54 Mn |
| Mar 31, 2024 | 86.54 Mn |
| Dec 31, 2023 | -1.33 Mn |
| Dec 31, 2023 | -1.33 Mn |